Emerging and Investigational Therapies

This chapter surveys emerging and investigational therapeutic approaches for ME/CFS identified through novel immunophenotyping, cross-disease mechanistic inference, and targeted pathway intervention. None of the therapies discussed have completed randomised controlled trials for ME/CFS; they are presented as mechanistically motivated research directions with explicit certainty ratings rather than clinical recommendations. Patient safety, particularly for severe and very-severe patients, and the need for rigorous clinical trial validation are emphasised throughout.

NoteChapter Roadmap: How to Use This Chapter

For patients: the only immediately actionable item is the emergency PEM prevention protocol (Emergency PEM Prevention Protocol) — but it is speculative and unvalidated; discuss with your physician first. Everything else is research-stage.

For caregivers: the PEM prevention protocol may help you prepare a crash response, but treat it as a hypothesis, not an established protocol, for a severe patient.

For clinicians: read the sigma-1 receptor / fluvoxamine section (Sigma-1 Receptor Mechanisms and Fluvoxamine Therapy) and the AIMM sodium-calcium correction proposal (Sigma-1 Receptor Mechanisms and Fluvoxamine Therapy) as the closest to clinical consideration; the immune, B-cell, and NET-targeting sections are trial-stage only.

For researchers: the primary audience — the immune-trafficking, costimulatory, B-cell-targeted, and NET-targeting speculations each carry a certainty rating and falsifiable prediction for hypothesis testing.

1 Contents